LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome

LRG1 mRNA expression in breast cancer associates with PIK3CA genotype and with aromatase inhibitor therapy outcome

Background PIK3CA is the most frequent somatic mutated oncogene in estrogen receptor (ER) positive breast cancer. We previously observed an association between PIK3CA genotype and aromatase inhibitors (AI) treatment outcome. This study now evaluates whether expression of mRNAs and miRs are linked to...

Full description

Bibliographic Details
Main Authors: Diana E. Ramirez-Ardila, Kirsten Ruigrok-Ritstier, Jean C. Helmijr, Maxime P. Look, Steven van Laere, Luc Dirix, Els M.J.J. Berns, Maurice P.H.M. Jansen
Format: Article
Language:English
Published: Wiley 2016-10-01
Series:Molecular Oncology
Subjects:
PIK3CA mutations
Breast cancer
First line aromatase inhibitors therapy
LRG1
Online Access:https://doi.org/10.1016/j.molonc.2016.07.004

Internet

https://doi.org/10.1016/j.molonc.2016.07.004

Similar Items